Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

NCT00103948 is registered in ClinicalTrials.gov with Eisai Limited as lead sponsor.

NCT NCT00103948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00103948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment
Lead sponsor
Eisai Limited
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2005
Completion date
February 28, 2007
Enrollment
165 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment